Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human LEPREL1 ELISA Kit (AC3087)
Cat.#: ASET-1676
Specifications
Description Human LEPREL1 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human LEPREL1 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 9.22 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 200-3200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1215 Human BDNF ELISA Kit (AC2626) Quantitative inquiry ASET-2128 Human Chromogranin A ELISA Kit (AC3539) Quantitative inquiry ASET-1036 Mouse TIMP1 ELISA Kit (AC2447) Quantitative inquiry ASET-2462 Human Zyxin ELISA Kit (AC3873) Quantitative inquiry ASET-1424 Human Semaphorin 3F ELISA Kit (AC2835) Quantitative inquiry ASET-1869 Human Nogo ELISA Kit (AC3280) Quantitative inquiry ASET-1379 Human CD11b ELISA Kit (AC2790) Quantitative inquiry ASET-1943 Mouse NK-2R ELISA Kit (AC3354) Quantitative inquiry ASET-1911 Mouse c-Fos ELISA Kit (AC3322) Quantitative inquiry ASET-1418 Mouse Aromatase ELISA Kit (AC2829) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket